MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Roivant Sciences Ltd

Cerrado

SectorSanidad

17.26 1.05

Resumen

Variación precio

24h

Actual

Mínimo

16.88

Máximo

17.31

Métricas clave

By Trading Economics

Ingresos

-22M

-274M

Ventas

-5.4M

2.2M

Margen de beneficios

-12,622.627

Empleados

750

EBITDA

-284K

-284M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+19.54% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.4B

11B

Apertura anterior

16.21

Cierre anterior

17.26

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

170 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

16 oct 2025, 21:10 UTC

Principales Movimientos del Mercado

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16 oct 2025, 19:03 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16 oct 2025, 17:58 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16 oct 2025, 17:12 UTC

Ganancias

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16 oct 2025, 17:12 UTC

Adquisiciones, fusiones, absorciones

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16 oct 2025, 16:59 UTC

Adquisiciones, fusiones, absorciones

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16 oct 2025, 23:44 UTC

Charlas de Mercado

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16 oct 2025, 23:42 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:15 UTC

Ganancias

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16 oct 2025, 22:15 UTC

Ganancias

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16 oct 2025, 22:02 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 22:02 UTC

Charlas de Mercado

Santos Drifts Into 'Oversold Territory' -- Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 20:23 UTC

Charlas de Mercado

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16 oct 2025, 20:20 UTC

Ganancias

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16 oct 2025, 20:08 UTC

Adquisiciones, fusiones, absorciones

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16 oct 2025, 19:37 UTC

Adquisiciones, fusiones, absorciones

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16 oct 2025, 19:26 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 19:24 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16 oct 2025, 19:23 UTC

Charlas de Mercado

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16 oct 2025, 19:23 UTC

Ganancias

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16 oct 2025, 18:35 UTC

Charlas de Mercado
Ganancias

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 oct 2025, 18:31 UTC

Charlas de Mercado

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16 oct 2025, 16:57 UTC

Charlas de Mercado

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

19.54% repunte

Estimación a 12 Meses

Media 20.31 USD  19.54%

Máximo 24 USD

Mínimo 16 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

7

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

170 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
help-icon Live chat